Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ARCT

ARCT - Arcturus Therapeutics Holdings Inc Stock Price, Fair Value and News

37.59USD+0.15 (+0.40%)Delayed as of 23 Feb 2024, 11:04 am ET
Watchlist

Market Summary

USD37.59+0.15
Delayedas of 23 Feb 2024, 11:04 am
0.40%

ARCT Alerts

  • ARK Investment Management LLC reported owning 7.66% of ARCT [2024-01-29]

ARCT Stock Price

View Fullscreen

ARCT RSI Chart

ARCT Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

10.07

Price/Sales (Trailing)

3.38

EV/EBITDA

6.62

Price/Free Cashflow

7.31

ARCT Price/Sales (Trailing)

ARCT Profitability

EBT Margin

34.50%

Return on Equity

35.47%

Return on Assets

21.7%

Free Cashflow Yield

13.69%

ARCT Fundamentals

ARCT Revenue

Revenue (TTM)

296.2M

Rev. Growth (Yr)

237.65%

Rev. Growth (Qtr)

329.13%

ARCT Earnings

Earnings (TTM)

99.3M

Earnings Growth (Yr)

54%

Earnings Growth (Qtr)

69.13%

Breaking Down ARCT Revenue

52 Week Range

14.2137.96
(Low)(High)

Last 7 days

-6.9%

Last 30 days

11.4%

Last 90 days

47.7%

Trailing 12 Months

92.9%

How does ARCT drawdown profile look like?

ARCT Financial Health

Current Ratio

4.49

Debt/Equity

0.07

Debt/Cashflow

7.14

ARCT Investor Care

Shares Dilution (1Y)

0.87%

Diluted EPS (TTM)

3.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023281.0M264.5M296.2M0
202215.5M40.6M51.5M206.0M
20219.0M8.7M8.8M12.4M
202019.1M11.3M10.3M9.5M
201917.0M18.3M19.5M20.8M
201800015.8M

Tracking the Latest Insider Buys and Sells of Arcturus Therapeutics Holdings Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 01, 2023
chivukula pad
sold
-93,601
18.7203
-5,000
chief scientific officer & coo
Oct 02, 2023
chivukula pad
sold
-128,062
25.6123
-5,000
chief scientific officer & coo
Sep 01, 2023
chivukula pad
sold
-157,264
31.4527
-5,000
chief scientific officer & coo
Aug 15, 2023
sassine andy
acquired
21,248
17.374
1,223
chief financial officer
Aug 01, 2023
chivukula pad
sold
-174,550
34.91
-5,000
chief scientific officer & coo
Jul 14, 2023
kummerfeld keith c
sold
-243,880
35.00
-6,968
see remarks
Jul 14, 2023
kummerfeld keith c
acquired
62,408
8.95642
6,968
see remarks
Jul 14, 2023
chivukula pad
sold
-875,250
35.01
-25,000
chief scientific officer & coo
Jul 03, 2023
chivukula pad
sold
-143,750
28.75
-5,000
chief scientific officer & coo
Jun 01, 2023
chivukula pad
sold
-135,800
27.16
-5,000
chief scientific officer & coo

1–10 of 50

Which funds bought or sold ARCT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
2.29
106,000
508,000
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
new
-
88,915
88,915
-%
Feb 15, 2024
Legal & General Group Plc
added
3.35
143,057
662,540
-%
Feb 15, 2024
Virtus ETF Advisers LLC
reduced
-7.82
12,592
104,112
0.07%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-9.63
232,324
2,249,850
-%
Feb 15, 2024
Financial Gravity Asset Management, Inc.
sold off
-
-7.00
7.00
-%
Feb 15, 2024
DAGCO, INC.
new
-
20,495
20,495
0.02%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
1,608
1,608
-%
Feb 15, 2024
BARCLAYS PLC
reduced
-24.86
-209,000
2,664,000
-%
Feb 14, 2024
Graham Capital Management, L.P.
added
56.03
202,071
420,421
0.01%

1–10 of 42

Are Funds Buying or Selling ARCT?

Are funds buying ARCT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARCT
No. of Funds

Unveiling Arcturus Therapeutics Holdings Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.46%
1,458,380
SC 13G/A
Feb 12, 2024
nikko asset management americas, inc.
4.94%
1,320,652
SC 13G/A
Feb 05, 2024
sumitomo mitsui trust holdings, inc.
4.94%
1,320,652
SC 13G/A
Jan 29, 2024
ark investment management llc
7.66%
2,047,687
SC 13G/A
Jan 25, 2024
blackrock inc.
9.0%
2,398,296
SC 13G/A
Jan 25, 2024
state street corp
6.10%
1,629,666
SC 13G/A
Jan 17, 2024
federated hermes, inc.
17.63%
4,711,512
SC 13G/A
Oct 10, 2023
state street corp
6.27%
1,667,925
SC 13G/A
Feb 10, 2023
nikko asset management americas, inc.
5.45%
1,449,060
SC 13G/A
Feb 10, 2023
ark investment management llc
7.58%
2,012,429
SC 13G/A

Recent SEC filings of Arcturus Therapeutics Holdings Inc

View All Filings
Date Filed Form Type Document
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Feb 05, 2024
SC 13G/A
Major Ownership Report
Jan 29, 2024
SC 13G/A
Major Ownership Report
Jan 25, 2024
SC 13G/A
Major Ownership Report
Jan 25, 2024
SC 13G/A
Major Ownership Report
Jan 17, 2024
SC 13G/A
Major Ownership Report
Dec 19, 2023
4
Insider Trading
Dec 19, 2023
4
Insider Trading
Dec 19, 2023
4
Insider Trading

What is the Fair Value of ARCT?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Arcturus Therapeutics Holdings Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Arcturus Therapeutics Holdings Inc News

Latest updates
Seeking Alpha25 hours ago

Arcturus Therapeutics Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue329.1%45,140,00010,519,00080,285,000160,293,00013,369,00027,093,0005,244,0005,794,0002,437,0002,001,0002,127,0002,238,0002,333,0002,322,0002,646,0002,968,0003,318,00010,153,0004,350,0003,886,5003,423,000
Operating Expenses-2.2%64,454,00065,893,00065,530,00038,841,00050,176,00049,182,00055,623,00043,439,00056,258,00055,721,00059,793,00033,320,00023,271,00012,364,00012,108,00013,785,00010,934,00010,725,00010,858,000-7,779,000
  S&GA Expenses1.1%13,377,00013,225,00013,762,00011,860,00012,488,00010,993,00010,730,00010,806,00010,860,00010,042,0009,743,0009,034,0005,572,0004,420,0004,191,0001,791,0003,881,0003,456,0003,534,000-3,810,000
  R&D Expenses-3.0%51,077,00052,668,00051,768,00026,981,00037,688,00038,189,00044,893,00032,633,00045,398,00045,679,00050,050,00024,286,00017,699,0007,944,0007,917,00011,994,0007,053,0007,269,0007,324,000-3,969,000
EBITDA Margin9.9%0.360.330.420.06-3.91-4.97-13.05-16.33-------------
Interest Expenses---2,102,000228,000230,000186,000169,000170,000173,000172,000169,000578,000-7,000-48,000228,000183,000168,000173,000167,000--
Income Taxes56.0%900,000577,000100,000---100,000--------------
Earnings Before Taxes70.5%-15,329,000-51,973,00050,857,000118,642,000-35,266,000-21,563,000-51,169,000--------------
EBT Margin10.9%0.340.310.400.05-3.95-5.02-13.16-16.48-------------
Net Income69.1%-16,222,000-52,550,00050,754,000117,347,000-35,266,000-21,563,000-51,169,000-38,663,000-54,084,000-54,581,000-56,346,000-31,104,000-21,004,000-10,263,000-9,777,000-10,989,000-7,433,000-685,000-6,884,000--4,253,000
Net Income Margin10.5%0.340.300.400.05-2.85-4.08-12.83-16.48-22.28-18.74-13.16-7.56---------
Free Cashflow-166.2%-33,387,00050,453,000-36,562,000156,452,000-44,592,000-36,443,000-51,150,000-43,615,000-18,419,000-33,347,000-43,068,000-7,329,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets6.3%45843147145029433734239343544948147632315072.0082.0087.0071.0058.0044.00
  Current Assets2.1%39338542540324729232737942143847046831414264.0074.0079.0063.00-42.00
    Cash Equivalents-3.6%31232332839223828332037341443446746330713659.0071.0074.0056.0031.0037.00
  Net PPE-0.1%13.0013.0013.0012.0011.009.008.006.005.003.003.003.003.003.003.002.002.002.00-2.00
Liabilities22.1%17814514218014816615716517514312980.0061.0057.0055.0056.0051.0049.0040.0031.00
  Current Liabilities-2.9%88.0090.0090.0012776.0093.0010710011871.0053.0050.0028.0023.0022.0021.0022.0016.00-13.00
  Long Term Debt-20.00---32.0036.0039.0041.0042.0056.0058.0014.0015.0015.0015.0015.0010.0010.00-10.00
    LT Debt, Current----61.0028.0027.0024.0022.00---1.00--------
    LT Debt, Non Current-20.00---32.0036.0039.0041.0042.0056.0058.0014.0015.0015.0015.0015.0010.0010.00-10.00
Shareholder's Equity-1.8%28028532927014617118522825930635339726293.0017.0026.0036.0022.006.0014.00
  Retained Earnings-4.8%-356-339-287-338-455-420-398-347-308-254-200-143-112-91.71-81.44-71.70-60.68-53.25--44.87
  Additional Paid-In Capital1.8%63662561760860159158357656856055354037418598.0097.0097.0075.00-58.00
Shares Outstanding0.6%27.0027.0027.0027.0026.0026.0026.0026.0026.0026.0026.0026.00--------
Float------376---700---701---76.00--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-163.8%-32,40650,807-35,871160,259-42,406-36,821-49,039-42,497-16,653-32,943-42,950-6,632-15,877-8,494-11,858-7,538-2,8369,340-5,411--
  Share Based Compensation10.6%9,2698,3838,1826,5309,4367,2747,3717,5186,8707,5406,9872,8261,9881,101849797383403399--
Cashflow From Investing-177.1%-981-354-691-3,807-2,186378-2,111-1,118-1,766-404-118-697-434-469-142-315-159-266-78.00--
Cashflow From Financing23134.0%21,84094.00-27,364-2,232-1,22025733623069282.0047,012163,201187,22385,6031185,03421,327----

ARCT Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Total revenue$ 45,140$ 13,369$ 135,944$ 45,706
Operating expenses:    
Research and development, net51,07737,688155,513120,770
General and administrative13,37712,48840,36434,211
Total operating expenses64,45450,176195,877154,981
Loss from operations(19,314)(36,807)(59,933)(109,275)
Loss from equity-method investment   (515)
Gain (loss) from foreign currency41,862(175)3,237
Gain on debt extinguishment  33,953 
Finance income (expense), net3,981(321)9,710(1,445)
Net loss before income taxes(15,329)(35,266)(16,445)(107,998)
Provision for income taxes893 1,573 
Net loss$ (16,222)$ (35,266)$ (18,018)$ (107,998)
Net loss per share:    
Basic$ (0.61)$ (1.33)$ (0.68)$ (4.09)
Diluted$ (0.61)$ (1.33)$ (0.68)$ (4.09)
Weighted-average shares outstanding:    
Basic26,57426,46726,55926,423
Diluted26,57426,46726,55926,423
Comprehensive loss:    
Net loss$ (16,222)$ (35,266)$ (18,018)$ (107,998)
Comprehensive loss(16,222)(35,266)(18,018)(107,998)
Collaboration Revenue [Member]    
Revenue:    
Total revenue43,376$ 13,369132,670$ 45,706
Grant Revenue [Member]    
Revenue:    
Total revenue$ 1,764 $ 3,274 

ARCT Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 311,918$ 391,883
Restricted cash35,000 
Accounts receivable38,2202,764
Prepaid expenses and other current assets8,1308,686
Total current assets393,268403,333
Property and equipment, net12,71512,415
Operating lease right-of-use asset, net29,53432,545
Non-current restricted cash22,1332,094
Total assets457,650450,387
Current liabilities:  
Accounts payable18,3627,449
Accrued liabilities28,55330,232
Current portion of long-term debt 60,655
Deferred revenue40,76828,648
Total current liabilities87,683126,984
Deferred revenue, net of current portion41,91120,071
Long-term debt20,000 
Operating lease liability, net of current portion27,01830,216
Other non-current liabilities9762,804
Total liabilities177,588180,075
Stockholders’ equity  
Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,723 at September 30, 2023 and 26,555 at December 31, 20222727
Additional paid-in capital636,194608,426
Accumulated deficit(356,159)(338,141)
Total stockholders’ equity280,062270,312
Total liabilities and stockholders’ equity$ 457,650$ 450,387
ARCT
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
 CEO
 WEBSITEarcturusrx.com
 EMPLOYEES170

Arcturus Therapeutics Holdings Inc Frequently Asked Questions


What is the ticker symbol for Arcturus Therapeutics Holdings Inc? What does ARCT stand for in stocks?

ARCT is the stock ticker symbol of Arcturus Therapeutics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcturus Therapeutics Holdings Inc (ARCT)?

As of Thu Feb 22 2024, market cap of Arcturus Therapeutics Holdings Inc is 1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARCT stock?

You can check ARCT's fair value in chart for subscribers.

What is the fair value of ARCT stock?

You can check ARCT's fair value in chart for subscribers. The fair value of Arcturus Therapeutics Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcturus Therapeutics Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcturus Therapeutics Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether ARCT is over valued or under valued. Whether Arcturus Therapeutics Holdings Inc is cheap or expensive depends on the assumptions which impact Arcturus Therapeutics Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARCT.

What is Arcturus Therapeutics Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ARCT's PE ratio (Price to Earnings) is 10.07 and Price to Sales (PS) ratio is 3.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Arcturus Therapeutics Holdings Inc's stock?

In the past 10 years, Arcturus Therapeutics Holdings Inc has provided -0.132 (multiply by 100 for percentage) rate of return.